Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ORGS | US
-0.05
-11.11%
Healthcare
Biotechnology
30/06/2024
13/03/2026
0.40
0.40
0.40
0.40
Orgenesis Inc. a biotech company focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown Maryland.
View LessLow Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
265.5%1 month
1525.4%3 months
1356.3%6 months
10926.5%-
-
1.26
-0.84
0.43
-4.98
42.89
-
-19.06M
1.91M
1.91M
-
-1.65K
-
117.70
-727.25
2.39
1.33
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.30
Range1M
0.45
Range3M
0.60
Rel. volume
0.37
Price X volume
40.00
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| BioRestorative Therapies Inc | BRTX | Biotechnology | 0.3029 | 2.10M | -1.66% | n/a | 0.77% |
| Vaccinex Inc - Ordinary Shares | VCNX | Biotechnology | 0.7 | 1.82M | 27.27% | n/a | -4.26% |
| Dermata Therapeutics Inc. Common Stock | DRMA | Biotechnology | 1.19 | 1.80M | -4.03% | n/a | 0.00% |
| Allarity Therapeutics Inc. Common Stock | ALLR | Biotechnology | 1.26 | 1.78M | -6.67% | n/a | 6.68% |
| ERNA | ERNA | Biotechnology | 0.3241 | 1.75M | 4.89% | n/a | -577.12% |
| Kala Pharmaceuticals Inc | KALA | Biotechnology | 0.28 | 1.53M | -5.66% | n/a | 268.29% |
| Plus Therapeutics Inc | PSTV | Biotechnology | 0.25 | 1.47M | -15.17% | n/a | -45.04% |
| International Stem Cell Corporation | ISCO | Biotechnology | 0.1761 | 1.41M | n/a | 0.00% | |
| Azitra Inc | AZTR | Biotechnology | 0.171 | 1.30M | -5.00% | 0.01 | 41.86% |
| XORTX Therapeutics Inc. Common Stock | XRTX | Biotechnology | 0.401 | 1.21M | -10.89% | n/a | 3.09% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.39 | 1.32M | -0.42% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -4.98 | - | Cheaper |
| Ent. to Revenue | 42.89 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.26 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 1,356.26 | - | Riskier |
| Debt to Equity | -0.84 | -1.23 | Expensive |
| Debt to Assets | 0.43 | 0.25 | Expensive |
| Market Cap | 1.91M | - | Emerging |